GLAND — Gland Pharma Income Statement
0.000.00%
Last trade - 00:00
- IN₹295.54bn
- IN₹277.67bn
- IN₹36.25bn
- 82
- 10
- 66
- 54
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 20,442 | 26,332 | 34,629 | 44,007 | 36,246 |
Cost of Revenue | |||||
Gross Profit | 11,609 | 14,970 | 19,247 | 22,514 | 18,913 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 14,398 | 17,724 | 22,594 | 30,007 | 28,030 |
Operating Profit | 6,044 | 8,609 | 12,034 | 14,000 | 8,216 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 6,863 | 9,929 | 13,348 | 16,186 | 10,546 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4,519 | 7,729 | 9,970 | 12,117 | 7,810 |
Net Income Before Extraordinary Items | |||||
Net Income | 4,519 | 7,729 | 9,970 | 12,117 | 7,810 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 4,519 | 7,729 | 9,970 | 12,117 | 7,810 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 28.5 | 46.5 | 63 | 73.6 | 50.3 |
Dividends per Share |